Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 18/20 | 0.51 |
| ▸ | CHUK | O15111 | 6/20 | 0.51 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.50 |
| ▸ | BTK | Q06187 | 2/20 | 0.48 |
| ▸ | AURKA | O14965 | 1/20 | 0.48 |
| ▸ | FLT3 | P36888 | 1/20 | 0.48 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.48 |
| ▸ | CSF1R | P07333 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4685993 | 0.86 | IKBKB (0.66) | IKBKBCHUKBTKAURKAFLT3 | |
| SCHEMBL5524853 | 0.86 | IKBKB (0.51) | IKBKBCHUKBTKAURKAFLT3 | |
| SCHEMBL14019045 | 0.86 | IKBKB (0.57) | IKBKBCHUKBTKAURKAFLT3 | |
| SCHEMBL3800446 | 0.85 | IKBKB (0.51) | IKBKBCHUKGPR119BTKAURKA | |
| SCHEMBL4688385 | 0.84 | IKBKB (0.56) | IKBKBCHUKBTKAURKAFLT3 | |
| SCHEMBL3393221 | 0.84 | GPR119 (0.49) | GPR119 | |
| SCHEMBL3798256 | 0.83 | IKBKB (0.64) | IKBKBCHUKBTKAURKAFLT3 | |
| SCHEMBL4689145 | 0.83 | IKBKB (0.55) | IKBKBCHUKBTKAURKAFLT3 | |
| SCHEMBL4688238 | 0.83 | HTT (0.54) | IKBKBCHUKGPR119BTKAURKA | |
| SCHEMBL14018415 | 0.82 | IKBKB (0.47) | IKBKBCHUKGPR119BTKAURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7858796-B2 | Chemical compounds | GLAXO GROUP LIMITED (GB) | 2010-12-28 | — | — | US | disclosed |
| US-7858796-B2 | Chemical compounds | GLAXO GROUP LIMITED (GB) | 2010-12-28 | — | — | US | disclosed |
| US-7858796-B2 | Chemical compounds | GLAXO GROUP LIMITED (GB) | 2010-12-28 | — | — | US | disclosed |
| EP-1703905-B1 | INDOLE DERIVATIVES AND USE THEREOF AS KINASE INHIBITORS IN PARTICULAR IKK2 INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2008-11-12 | — | — | EP | disclosed |
| EP-1703905-B1 | INDOLE DERIVATIVES AND USE THEREOF AS KINASE INHIBITORS IN PARTICULAR IKK2 INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2008-11-12 | — | — | EP | disclosed |
| US-20080269200-A1 | Indole Derivatives and Use Thereof as Kinase Inhibitors in Particular Ikk2 Inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2008-10-30 | — | — | US | disclosed |
| US-20080269200-A1 | Indole Derivatives and Use Thereof as Kinase Inhibitors in Particular Ikk2 Inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2008-10-30 | — | — | US | disclosed |
| US-20080269200-A1 | Indole Derivatives and Use Thereof as Kinase Inhibitors in Particular Ikk2 Inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2008-10-30 | — | — | US | disclosed |
| US-20070254873-A1 | Chemical Compounds | GLAXO GROUP LIMITED (GB) | 2007-11-01 | — | — | US | disclosed |
| US-20070254873-A1 | Chemical Compounds | GLAXO GROUP LIMITED (GB) | 2007-11-01 | — | — | US | disclosed |
| US-20070254873-A1 | Chemical Compounds | GLAXO GROUP LIMITED (GB) | 2007-11-01 | — | — | US | disclosed |
| EP-1703905-A1 | INDOLE DERIVATIVES AND USE THEREOF AS KINASE INHIBITORS IN PARTICULAR IKK2 INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-09-27 | — | — | EP | disclosed |
| WO-2005067923-A1 | INDOLE DERIVATIVES AND USE THEREOF AS KINASE INHIBITORS IN PARTICULAR IKK2 INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-07-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254873-A1 | Chemical Compounds | IKBKG, NFKBIA, RELA | IKBKB 5/4885CHUK 9/4885GPR119 1435/4885 |
| US-20080269200-A1 | Indole Derivatives and Use Thereof as Kinase Inhibitors in Particular Ikk2 Inhibitors | NFKBIA, IKBKB, IDO2 | IKBKB 2/4885CHUK 6/4885GPR119 1140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.